Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01377922 · ClinicalTrials.gov registry record · Phase 3
A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)
A Phase 3 study of Lambert-eaton Myasthenic Syndrome, sponsored by Catalyst Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 38
- Enrollment target
- 14
- Study locations
NCT01377922 is a Phase 3 study of Lambert-eaton Myasthenic Syndrome that has completed, run by Catalyst Pharmaceuticals. The registered enrollment target is 38 participants. The trial reports 14 study locations across 7 states.
The verdict
NCT01377922, a Phase 3 study of Lambert-eaton Myasthenic Syndrome, has completed, sponsored by Catalyst Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 38 participants
- Enrollment target
- 14
- Study locations
Study Summary
A Phase 3 study to evaluate the efficacy and safety of Amifampridine Phosphate in patients with Lambert-Eaton Myasthenic Syndrome (LEMS).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Amifampridine Phosphate
Study Locations (14)
Other
- - Lyon
- - Berlin
- - Pécs
- - Warsaw
- - Moscow
- - Belgrade
- - Madrid
California
- - Los Angeles
- - Palo Alto
Alabama
- - Birmingham
Arizona
- - Scottsdale
Kansas
- - Kansas City
New York
- - New York
Bavaria
- - Munich
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2011-06 |
| Est. Completion | 2016-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01377922
The ClinicalTrials.gov registry entry for NCT01377922 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Catalyst Pharmaceuticals, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lambert-eaton Myasthenic Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01377922 reports 14 study locations spanning 7 distinct geographic areas - top geographies include Other, California, Alabama.
Frequently Asked Questions
What is clinical trial NCT01377922 about?
NCT01377922 is a clinical study titled "A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)". A Phase 3 study to evaluate the efficacy and safety of Amifampridine Phosphate in patients with Lambert-Eaton Myasthenic Syndrome (LEMS).
What is the current status of trial NCT01377922?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 38 participants. The study started on 2011-06. Estimated completion is 2016-07.
What conditions does trial NCT01377922 study?
This clinical trial studies the following conditions: Lambert-eaton Myasthenic Syndrome.
What interventions are being tested in trial NCT01377922?
The interventions under investigation include: Placebo (DRUG), Amifampridine Phosphate (DRUG).
Who is sponsoring clinical trial NCT01377922?
This trial is sponsored by Catalyst Pharmaceuticals, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01377922 being conducted?
This trial has 14 study locations across Alabama, Arizona, California, Kansas, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lambert-eaton Myasthenic Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.